<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515241</url>
  </required_header>
  <id_info>
    <org_study_id>CER-001-CLIN-005</org_study_id>
    <nct_id>NCT01515241</nct_id>
  </id_info>
  <brief_title>Exploratory Study of Plaque Regression</brief_title>
  <acronym>EXPRESS</acronym>
  <official_title>EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerenis Therapeutics, SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerenis Therapeutics, SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the availability of several classes of very effective drugs available to treat
      heterozygous Familial Hypercholesterolemia (HeFH), there remains a large unmet medical need
      for new, effective and well tolerated therapies. There are a number of therapies given on a
      chronic basis to reduce long term risk, such as statins, fibrates, niacin, omega 3 fatty
      acids, resins, cholesterol absorption inhibitors and antiplatelet or anticoagulant drugs, but
      subjects with heterozygous Familial Hypercholesterolemia remain at high risk for
      cardiovascular events. There is still a need for acute therapies that can lead to rapid
      pacification of unstable plaque in order to reduce the risk of these events. This study will
      assess the effects of CER-001 , a recombinant human Apo-A-1 based HDL mimetic, on indices of
      atherosclerotic plaque progression and regression as assessed by 3Tesla MRI (3TMRI)and
      intravascular ultrasound (IVUS) evaluations in patients with HeFH.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Plaque Volume</measure>
    <time_frame>Baseline and 3 weeks post final dose</time_frame>
    <description>Nominal change in total plaque volume (ACTPV), as assessed by 3D IVUS, from the baseline measurement to the follow-up taken ~3 weeks following the final dose of study medication (approximately 10 weeks after the baseline assessment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Plaque Volume</measure>
    <time_frame>Baseline and 3 weeks post final dose</time_frame>
    <description>Percent change in total plaque volume (PCTPV), as assessed by IVUS, from the baseline measurement to the follow up taken approximately 3 weeks following the final dose of study medication (approximately 10 weeks after the baseline assessment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in carotid plaque volume</measure>
    <time_frame>Baseline and 3 weeks post final dose</time_frame>
    <description>Percent change in total carotid plaque volume, as assessed by 3TMRI, from the baseline measurement to the follow up taken approximately 3 weeks following the final dose of study medication</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Heterozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Open label single arm study of CER-001</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open label single arm study of CER-001</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CER-001</intervention_name>
    <description>Weekly injection</description>
    <arm_group_label>Open label single arm study of CER-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female subjects at least 18 years old

          -  Subject presents heterozygous FH, known CHD and receiving maximally tolerated lipid
             modifying therapy, at stable doses for at least 3 months

          -  LDL-C of &gt; 110 mg/dl

          -  Angiographic evidence of coronary artery disease with suitable &quot;target&quot; coronary
             artery for IVUS

        Exclusion Criteria:

          -  Confirmed diagnosis of homozygous FH

          -  Significant health problems (other than cardiovascular disease) in the recent past
             including blood disorders, cancer, or digestive problems

          -  Female subjects not meeting the study definition of non child-bearing potential

          -  Use of an investigational agent within 30 days of the first CER-001 dose

          -  Receiving current lipid apheresis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude Tardif, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 1999 Aug 10;100(6):594-8.</citation>
    <PMID>10441095</PMID>
  </reference>
  <reference>
    <citation>Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):979-89.</citation>
    <PMID>10195926</PMID>
  </reference>
  <reference>
    <citation>Spieker LE, Sudano I, Hürlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Lüscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002 Mar 26;105(12):1399-402.</citation>
    <PMID>11914243</PMID>
  </reference>
  <reference>
    <citation>Nieuwdorp M, Vergeer M, Bisoendial RJ, op 't Roodt J, Levels H, Birjmohun RS, Kuivenhoven JA, Basser R, Rabelink TJ, Kastelein JJ, Stroes ES. Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Diabetologia. 2008 Jun;51(6):1081-4. doi: 10.1007/s00125-008-0975-2. Epub 2008 Apr 4.</citation>
    <PMID>18389214</PMID>
  </reference>
  <reference>
    <citation>Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, Woollard K, Lyon S, Sviridov D, Dart AM. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res. 2008 Nov 7;103(10):1084-91. doi: 10.1161/CIRCRESAHA.108.182063. Epub 2008 Oct 2.</citation>
    <PMID>18832751</PMID>
  </reference>
  <reference>
    <citation>Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003 Nov 5;290(17):2292-300.</citation>
    <PMID>14600188</PMID>
  </reference>
  <reference>
    <citation>Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodés-Cabau J; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007 Apr 18;297(15):1675-82. Epub 2007 Mar 26.</citation>
    <PMID>17387133</PMID>
  </reference>
  <reference>
    <citation>Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, Satler LF, Martin BD, Perlman TJ, Maltais JA, Weissman NJ, Fitzgerald PJ, Brewer HB Jr. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010 Jun 15;55(24):2727-35. doi: 10.1016/j.jacc.2009.12.067.</citation>
    <PMID>20538165</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <disposition_first_submitted>January 29, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 29, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 3, 2014</disposition_first_posted>
  <last_update_submitted>January 29, 2014</last_update_submitted>
  <last_update_submitted_qc>January 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heterozygous Familial Hypercholesterolemia</keyword>
  <keyword>Familial Hypercholesterolemia</keyword>
  <keyword>HDL mimetic</keyword>
  <keyword>ApoA-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

